IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Open accessThe DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Abstract
Programmed death-1-directed (PD-1-directed) immune checkpoint blockade results in durable antitumor activity in many advanced malignancies. Recent studies suggest that IFN-γ is a critical driver of programmed death ligand-1 (PD-L1) expression in cancer and host cells, and baseline intratumoral T cell infiltration may improve response likelihood to anti-PD-1 therapies, including pembrolizumab. However, whether quantifying T cell-inflamed microenvironment is a useful pan-tumor determinant of PD-1-directed therapy response has not been rigorously evaluated. Here, we analyzed gene expression profiles (GEPs) using RNA from baseline tumor samples of pembrolizumab-treated patients. We identified immune-related signatures correlating with clinical benefit using a learn-and-confirm paradigm based on data from different clinical studies of pembrolizumab, starting with a small pilot of 19 melanoma patients and eventually defining a pan-tumor T cell-inflamed GEP in 220 patients with 9 cancers. Predictive value was independently confirmed and compared with that of PD-L1 immunohistochemistry in 96 patients with head and neck squamous cell carcinoma. The T cell-inflamed GEP contained IFN-γ-responsive genes related to antigen presentation, chemokine expression, cytotoxic activity, and adaptive immune resistance, and these features were necessary, but not always sufficient, for clinical benefit. The T cell-inflamed GEP has been developed into a clinical-grade assay that is currently being evaluated in ongoing pembrolizumab trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The degree of tumor inflammation, as assessed by the presence of type I/II IFN signaling and infiltrating effector T cells, is associated with an improved response to checkpoint immunotherapy (8–11,13).”
From Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis (2019) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Defects associated with this pathway and its downstream effectors have shown both negative and positive correlations with response to ICB, suggesting a dual role for this pathway in tumor immunity (Ayers et al., 2017; Gao et al., 2016).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Ayers et al., 2017
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Several gene signatures capturing the inflamed components of the TME have been associated with a favourable response to ICIs69,72,78–81, but none has been clinically validated thus far.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Interferon (IFN) signaling through the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway plays a prominent role in tumor immunity.”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Ayers et al., 2017
The cited source says what the claim attributes to it.
In the citing paper
“In the clinic, a strong IFN-γ signature has been identified as a useful predictor and indicator of response in anti-PD-1-treated patients across various cancer indications (75,92,93).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [93]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Regularization and Variable Selection Via the Elastic Net
Zou, H., & Hastie, T. (2005) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.1467-9868.2005.00503.x · Cited by 20,957
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 1×
“org Volume 127 Number 8 August 2017 Introduction Cancer cells have the ability to adapt to and avoid host immune checkpoints and surveillance as a means to promote their continued survival (1, 2).”
BackgroundMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“These data extend the observations of previous reports showing that CD8+ T lymphocytes and T cell active chemokines and T cell counterinhibitory molecules such as PD-1/PD-L1 and IDO1 are coregulated within tumors (4, 15, 21, 22) and confirm that response to anti–PD-1 blockade occurs primarily in patients with such a p…”
ResultSelf-citationPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · cited 1×
“Newer genomic technologies can be used to evaluate complexities of tumor and Recently, increased PD-L1 expression on the surface of tumor cells has been identified as an important determinant of response to immune therapies targeting the PD-1 axis (16).”
BackgroundSelf-citationPD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231 · cited 2×
“Likewise, these data provide a much higher level of statistical validation across multiple tumor types than has previously been reported for single genes associated with the IFN-γ signaling pathway and response to PD-1 blockade (17), indicating that integrated multigene signatures might represent more robust predictiv…”
Background
Cited by
Items 401–500 of 1,011
Multiomic analysis and immunoprofiling reveal distinct subtypes of human angiosarcoma
Chan, J. Y., Lim, J. Q., Yeong, J. P.-S., Ravi, V., Guan, P., Boot, A., Tay, T. K. Y., Selvarajan, S., Nasir, N. D. M., Loh, J. H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci139080 · Cited by 119
“TIS scores were highest within this cluster, suggesting that this subgroup of angiosarcomas may benefit from checkpoint immunotherapy (22).”
BackgroundKatoh, Y., Yaguchi, T., Kubo, A., Iwata, T., Morii, K., Kato, D., Ohta, S., Satomi, R., Yamamoto, Y., Oyamada, Y., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004616 · Cited by 124
Oncolytic Parapoxvirus induces Gasdermin E-mediated pyroptosis and activates antitumor immunity
Lin, J., Sun, S., Zhao, K., Gao, F., Wang, R., Li, Q., Zhou, Y., Zhang, J., Li, Y., Wang, X., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-35917-2 · Cited by 126
Liu, C., Chen, Z., Chen, K., Liao, F.-T., Chung, C.-E., Liu, X., Lin, Y., Keohavong, P., Leikauf, G. D., & Di, Y. P. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1994 · Cited by 123
Zheng, G., Guo, Z., Li, W., Xi, W., Zuo, B., Zhang, R., Wen, W., Yang, A., & Jia, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00629-w · Cited by 120
Waks, A. G., Stover, D. G., Guerriero, J. L., Dillon, D. A. R., Barry, W. T., Gjini, E., Hartl, C., Lo, W., Savoie, J., Brock, J. E., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0173 · Cited by 121
Takada, K., Sugita, S., Murase, K., Kikuchi, T., Oomori, G., Ito, R., Hayasaka, N., Miyanishi, K., Iyama, S., Ikeda, H., et al. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13215 · Cited by 115
Directing Traffic: How to Effectively Drive T Cells into Tumors
Anandappa, A. J., Wu, C. J., & Ott, P. A. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0790 · Cited by 152
Lung metastases share common immune features regardless of primary tumor origin
García‐Mulero, S., Alonso, M. H., Pardo, J., Santos, C., Sanjuán, X., Salazar, R., Moreno, V. R., Piulats, J. M., & Pamplona, R. S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000491 · Cited by 124
Recent Advancements in Nanomedicine for ‘Cold’ Tumor Immunotherapy
Chen, Q., Sun, T., & Jiang, C. (2021) · Nano-Micro Letters · doi:10.1007/s40820-021-00622-6 · Cited by 124
Lissa, D., Takahashi, N., Desai, P. A., Manukyan, I., Schultz, C. W., Rajapakse, V. N., Velez, M. J., Mulford, D. A., Roper, N., Nichols, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29517-9 · Cited by 122
Miyamoto, T., Murakami, R., Hamanishi, J., Tanigaki, K., Hosoe, Y., Mise, N., Takamatsu, S., Mise, Y., Ukita, M., Taki, M., et al. (2022) · Institutional Repositories DataBase (IRDB) · doi:10.14989/doctor.k23801 · Cited by 112
The role of biomarkers in personalized immunotherapy
Sankar, K., Ye, J. C., Li, Z., Zheng, L., Song, W., & Hu-Lieskovan, S. (2022) · Biomarker Research · doi:10.1186/s40364-022-00378-0 · Cited by 111
PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential
Rotman, J., den Otter, L. A. S., Bleeker, M. C. G., Samuels, S., Heeren, A. M., Roemer, M. G. M., Kenter, G. G., Zijlmans, H. J. M. A. A., van Trommel, N. E., de Gruijl, T. D., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.596825 · Cited by 115
Tong, H., Sun, J., Fang, J., Zhang, M., Liu, H., Xia, R., Zhou, W., Liu, K., & Chen, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.859323 · Cited by 126
Kim, H., Park, S., Jeong, S., Lee, Y. J., Lee, H., Kim, C. G., Kim, K. H., Hong, S., Lee, J., Kim, S., et al. (2019) · Hepatology · doi:10.1002/hep.30881 · Cited by 116
Lepletier, A., Madore, J., O’Donnell, J. S., Johnston, R. L., Li, X.-Y., McDonald, E., Ahern, E. S., Kuchel, A., Eastgate, M. A., Pearson, S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3925 · Cited by 116
Zhang, J., Zhou, N., Lin, A., Luo, P., Chen, X., Deng, H., Kang, S., Guo, L., Zhu, W., & Zhang, J. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02668-8 · Cited by 125
“In addition, the expression profile of IFN-γ-related GEP can predict the clinical outcome of PD-1 treatment [43].”
BackgroundSelf-citationImmunotherapy in non-small cell lung cancer harbouring driver mutations
Addeo, A., Passaro, A., Malapelle, U., Banna, G. L., Subbiah, V., & Friedlaender, A. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102179 · Cited by 119
Uzhachenko, R. V., Bharti, V., Ouyang, Z., Blevins, A., Mont, S., Saleh, N., Lawrence, H. A., Shen, C., Chen, S., Ayers, G. D., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108944 · Cited by 110
Hu, J., Othmane, B., Yu, A., Li, H., Cai, Z., Chen, X., Ren, W., Chen, J., & Zu, X. (2021) · BMC Medicine · doi:10.1186/s12916-021-02163-6 · Cited by 123
Genetic immune escape landscape in primary and metastatic cancer
Martínez-Jiménez, F., Priestley, P., Shale, C., Baber, J., Rozemuller, E. H., & Cuppen, E. P. J. G. (2023) · Nature Genetics · doi:10.1038/s41588-023-01367-1 · Cited by 120
Dorta-Estremera, S. M., Hegde, V. L., Slay, R., Sun, R., Yanamandra, A. V., Nicholas, C., Nookala, S. M. K., Sierra, G., Curran, M. A., & Sastry, K. J. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0728-4 · Cited by 113
Rakaee, M., Kilvaer, T. K., Jamaly, S., Berg, T., Paulsen, E., Berglund, M., Richardsen, E. H., Andersen, S., Al‐Saad, S., Poehl, M., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01307-y · Cited by 114
CXCR6 expressing T cells: Functions and role in the control of tumors
Mabrouk, N., Tran, T., Sam, I., Pourmir, I., Gruel, N., Granier, C., Pineau, J., Gey, A., Kobold, S., Fabre, E., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1022136 · Cited by 121
“Anti-PD-1 antibodies which increase TRM also modulates CXCR6 (57) and in fact, molecular signatures including CXCR6 appear to predict response to immunotherapy (76, 77), underpinning the high relevance of the pathway.”
BackgroundKok, V. C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00268 · Cited by 113
Pan, J. W., Zabidi, M. M. A., Ng, P.-S., Meng, M., Hasan, S. N., Sandey, B., Sammut, S., Yip, C. H., Rajadurai, P., Rueda, O. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20173-5 · Cited by 126
“From left to right: ESTIMATE immune scores, GSVA using Bindea et al.’s (2013) combined immune gene set, GSVA using an expanded IFN-γ gene set (Ayers et al. 2017), IMPRES (Auslander et al. 2018), and CD8+ T-cell scores from CIBERSORT.”
MethodSingh, S., Kumar, S., Srivastava, R. K., Nandi, A., Thacker, G., Murali, H., Kim, S., Baldeon, M. A., Tobias, J. W., Blanco, M. A., et al. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0495-y · Cited by 109
Brown, L. C., Tucker, M. D., Sedhom, R., Schwartz, E. B., Zhu, J., Kao, C., Labriola, M., Gupta, R. T., Marin, D., Wu, Y. S., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001792 · Cited by 122
Yang, Z., Yan, G., Zheng, L., Gu, W., Liu, F., Chen, W., Cui, X., Wang, Y., Yang, Y., Chen, X., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1938890 · Cited by 123
de Sousa, L. G., Rajapakshe, K., Canales, J. R., Chin, R. L., Feng, L., Wang, Q., Barrese, T. Z., Massarelli, E., William, W., Johnson, F. M., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004232 · Cited by 120
Haddad, R. I., Seiwert, T. Y., Chow, L. Q. M., Gupta, S., Weiss, J., Gluck, I., Eder, J. P., Burtness, B. A., Tahara, M., Keam, B., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003026 · Cited by 118
Self-citationMansurov, A., Hosseinchi, P., Chang, K., Lauterbach, A. L., Gray, L. T., Alpar, A. T., Budina, E., Slezak, A. J., Kang, S., Cao, S., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00888-0 · Cited by 113
Self-citationGarralda, E., Sukari, A., Lakhani, N. J., Patnaik, A., Lou, Y., Im, S.-A., Golan, T., Geva, R., Wermke, M., de Miguel, M., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100639 · Cited by 101
“The increased antitumor activity observed in participants with PD-L1 CPS 1 tumors in the current study is consistent with the mechanism of action of immune checkpoint inhibition as PD-L1 expression correlates with other markers of immune infiltration.(21) A limitation of the current study is that it is a single-arm, n…”
ResultYeong, J. P.-S., Lim, J. C. T., Lee, B. T. K., Li, H., Ong, C. C. H., Thike, A. A., Yeap, W. H., Yang, Y. L., Lim, A. Y. H., Tay, T. K. Y., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0499-y · Cited by 108
Memmott, R. M., Wolfe, A. R., Carbone, D. P., & Williams, T. M. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.03.017 · Cited by 118
Castiglioni, A., Yang, Y., Williams, K., Gogineni, A., Lane, R. S., Wang, A. W., Shyer, J. A., Zhang, Z., Mittman, S., Gutierrez, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40398-4 · Cited by 116
Sidders, B. S., Zhang, P., Goodwin, K., O’Connor, G., Russell, D. L., Borodovsky, A., Armenia, J., McEwen, R. K., Linghu, B., Bendell, J. C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2183 · Cited by 107
Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy
Jing, Y., Zhang, Y., Wang, J., Li, K., Chen, X., Heng, J., Gao, Q., Ye, Y., Zhang, Z., Liu, Y., et al. (2021) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djab035 · Cited by 105
Huuhtanen, J., Kasanen, H. H. E., Peltola, K. J., Lönnberg, T., Glumoff, V., Brück, O. E., Dufva, O., Peltonen, K., Vikkula, J., Jokinen, E., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci164809 · Cited by 106
The Multifaceted Role of Th1, Th9, and Th17 Cells in Immune Checkpoint Inhibition Therapy
Lee, J., Lozano‐Ruiz, B., Yang, F. M., Fan, D. D., Shen, L., & González-Navajas, J. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.625667 · Cited by 147
Ascierto, P. A., Casula, M., Bulgarelli, J., Pisano, M., Piccinini, C., Piccin, L., Cossu, A., Mandalà, M., Ferrucci, P. F., Guidoboni, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44475-6 · Cited by 112
Tray, N., Weber, J. S., & Adams, S. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0214 · Cited by 106
Menon, D. R., Li, Y., Yamauchi, T., Osborne, D. G., Vaddi, P. K., Wempe, M. F., Zhai, Z., & Fujita, M. (2021) · Pharmaceuticals · doi:10.3390/ph14111081 · Cited by 106
Raufaste-Cazavieille, V., Santiago, R., & Droit, A. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.962743 · Cited by 110
“Other biomarkers derive from NGS test: tumor mutation burden (TMB) and the level of expression of interferon-gamma (IFNγ) or INFγ gene expression profile signature (Ayers et al., 2017; Nishino et al., 2017).”
BackgroundYu, J., Yan, J., Guo, Q., Chi, Z., Tang, B., Zheng, B., Yu, J., Yin, T., Cheng, Z., Wu, X., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0475 · Cited by 100
Lai, A. Y., Sorrentino, J. A., Dragnev, K. H., Weiss, J., Owonikoko, T. K., Rytlewski, J. A., Hood, J. V. W., Zhao, Y., Malik, R. K., Strum, J. C., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000847 · Cited by 105
Understanding CAR T cell-tumor interactions: Paving the way for successful clinical outcomes
Korell, F., Berger, T. R., & Maus, M. V. (2022) · Med · doi:10.1016/j.medj.2022.05.001 · Cited by 115
Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response
Roelands, J. P., Hendrickx, W., Zoppoli, G. M., Mall, R., Saad, M., Halliwill, K. D., Curigliano, G., Rinchai, D., Decock, J. V., Delogu, L. G., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000617 · Cited by 108
Ilyas, S. I., Wang, J., & El-Khoueiry, A. B. (2020) · Hepatology · doi:10.1002/hep.31416 · Cited by 118
The GPCR–Gαs–PKA signaling axis promotes T cell dysfunction and cancer immunotherapy failure
Wu, V. H., Yung, B. S., Faraji, F., Saddawi‐Konefka, R., Wang, Z., Wenzel, A. T., Song, M., Pagadala, M. S., Clubb, L. M., Chiou, J., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01529-7 · Cited by 104
Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types
Paré, L., Pascual, T., Seguí, E., Teixidó, C., González‐Cao, M., Galván, P., Rodríguez, A., González‐Farré, B., Cuatrecasas, M., Pineda, E., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy335 · Cited by 108
D’Alise, A. M., Leoni, G., Cotugno, G., Troise, F., Langone, F., Fichera, I., Lucia, M. D., Avalle, L., Vitale, R. L., Leuzzi, A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10594-2 · Cited by 102
Griffiths, J. I., Wallet, P., Pflieger, L. T., Stenehjem, D. D., Liu, X., Cosgrove, P. A., Leggett, N. A., McQuerry, J. A., Shrestha, G., Rossetti, M. M., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1918937117 · Cited by 109
“Patient responsiveness has been associated with increased tumor cell mutational load and antigen production (20, 21), and also with greater tumor-associated immune cell infiltration (22), signal production (14), and cross-talk (23).”
BackgroundHe, L., Fan, Y., Zhang, Y., Tu, T.-T., Zhang, Q., Yuan, F., & Cheng, C. (2022) · Journal of Pineal Research · doi:10.1111/jpi.12803 · Cited by 105
Alessi, J. V., Elkrief, A., Ricciuti, B., Wang, X., Cortellini, A., Vaz, V. R., Lamberti, G., Frias, R. L., Venkatraman, D., Fulgenzi, C. A. M., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.01.091 · Cited by 97
PTEN loss correlates with T cell exclusion across human cancers
Lin, Z., Huang, L., Li, S. L., Gu, J., Cui, X., & Zhou, Y. (2021) · BMC Cancer · doi:10.1186/s12885-021-08114-x · Cited by 106
Li, X., Lu, M., Yuan, M., Ye, J., Zhang, W., Xu, L., Wu, X., Hui, B., Yang, Y., Wei, B., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2118210 · Cited by 105
Multiomics and spatial mapping characterizes human CD8 + T cell states in cancer
Naulaerts, S., Datsi, A., Borràs, D., Antoranz, A., Messiaen, J., Vanmeerbeek, I., Sprooten, J., Laureano, R. S., Govaerts, J., Panovska, D., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.add1016 · Cited by 100
β-Catenin–mediated immune evasion pathway frequently operates in primary cutaneous melanomas
Nsengimana, J., Laye, J., Filia, A., O’Shea, S., Muralidhar, S., Poźniak, J., Droop, A., Chan, M., Walker, C., Parkinson, L., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci95351 · Cited by 96
DNA repair defects and implications for immunotherapy
Bever, K. M., & Le, D. T. (2018) · Journal of Clinical Investigation · doi:10.1172/jci122010 · Cited by 101
EBV-associated gastric cancer evades T-cell immunity by PD-1/PD-L1 interactions
Sasaki, S., Nishikawa, J., Sakai, K., Iizasa, H., Yoshiyama, H., Yanagihara, M., Shuto, T., Shimokuri, K., Kanda, T., Suehiro, Y., et al. (2018) · Gastric Cancer · doi:10.1007/s10120-018-0880-4 · Cited by 104
Song, K., Oh, S. J., Kim, S., Cho, H., Lee, H.-J., Song, J. S., Chung, J., Cho, E., Lee, J., Jeon, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14259-y · Cited by 105
FOXA1 overexpression suppresses interferon signaling and immune response in cancer
He, Y., Wang, L., Wei, T., Xiao, Y., Sheng, H., Su, H., Hollern, D. P., Zhang, X., Ma, J., Wen, S., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci147025 · Cited by 106
Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition
Engelsen, A. S. T., Lotsberg, M. L., Khouzam, R. A., Thiery, J. P., Lorens, J. B., Chouaïb, S., & Terry, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.869676 · Cited by 104
Rutella, S., Vadakekolathu, J. N., Mazziotta, F., Reeder, S., Yau, T. O., Mukhopadhyay, R., Dickins, B., Altmann, H., Krämer, M., Knaus, H. A., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci159579 · Cited by 106
Tumor microenvironment and immunotherapy for triple-negative breast cancer
Guo, Z., Zhu, Z., Lin, X., Wang, S., Wen, Y., Wang, L., Zhi, L., & Zhou, J. (2024) · Biomarker Research · doi:10.1186/s40364-024-00714-6 · Cited by 102
Onuma, A. E., Zhang, H., Huang, H., Williams, T. M., Noonan, A. M., & Tsung, A. (2020) · Gene Expression · doi:10.3727/105221620x15880179864121 · Cited by 99
Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade
Lei, Y., Li, X., Huang, Q., Zheng, X., & Liu, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.617335 · Cited by 101
Neutrophils Extracellular Traps Inhibition Improves PD-1 Blockade Immunotherapy in Colorectal Cancer
Zhang, H., Wang, Y., Onuma, A. E., He, J., Wang, H., Xia, Y., Lal, R., Cheng, X., Kasumova, G. G., Hu, Z., et al. (2021) · Cancers · doi:10.3390/cancers13215333 · Cited by 99
Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies
Zhou, S., & Yang, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1129465 · Cited by 122
“An analysis of gene expression profiles for pembrolizumab-treated patients found that IFN-g-related mRNA profile could predict clinical response to PD-1 inhibitor (60).”
BackgroundHuang, X., Hu, M., Sun, T., Li, J., Zhou, Y., Yan, Y., Xuan, B., Wang, J., Xiong, H., Ji, L., et al. (2023) · Cell Host & Microbe · doi:10.1016/j.chom.2023.10.005 · Cited by 104
de Rodas, M. L., Villalba-Esparza, M., Sanmamed, M. F., Chen, L., Rimm, D. L., & Schalper, K. A. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00984-x · Cited by 109
Flynn, M. J., Sayed, A. A., Sharma, R., Siddique, A., & Pinato, D. J. (2018) · Hepatology · doi:10.1002/hep.30337 · Cited by 98
“Enrichment of interferon-gamma (IFN-γ)-related signatures identified through transcriptomic profiling is a common trait of ICPI-responsive malignancies.(62) Microsatellite instability occurs because of defective mismatch repair (MMR) and leads to a somatic hypermutated phenotype with higher neoantigen burden.”
BackgroundMárquez-Rodas, I., Longo, F., Rodriguez-Ruiz, M. E., Calles, A., Ponce, S., Jove, M., Rubio-Viqueira, B., Perez-Gracia, J. L., Gómez-Rueda, A., López-Tarruella, S., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abb0391 · Cited by 88
Cai, L., Liu, H., Huang, F., Fujimoto, J., Girard, L., Chen, J., Li, Y., Zhang, Y.-A., Deb, D., Stastny, V., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-01842-7 · Cited by 103
Association between immune-related adverse event timing and treatment outcomes
Hsiehchen, D., Naqash, A. R., Espinoza, M., von Itzstein, M. S., Cortellini, A., Ricciuti, B., Owen, D. H., Laharwal, M., Toi, Y., Burke, M., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2021.2017162 · Cited by 99
Alemohammad, H., Najafzadeh, B., Asadzadeh, Z., Baghbanzadeh, A., Ghorbaninezhad, F., Najafzadeh, A., Safarpour, H., Bernardini, R., Brunetti, O., Sonnessa, M., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112516 · Cited by 92
Advances in the Treatment of Non–Small Cell Lung Cancer
Patel, S. A., & Weiss, J. (2020) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2020.02.010 · Cited by 98
Chen, L., Oke, T. F., Siegel, N. M., Cojocaru, G., Tam, A. J., Blosser, R. L., Swailes, J., Ligon, J. A., Lebid, A., Morris, C. D., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3416 · Cited by 95
Janku, F., Han, S.-W., Doi, T., Amatu, A., Ajani, J. A., Kuboki, Y., Cortez, A., Cellitti, S. E., Mahling, P. C., Subramanian, K., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0722 · Cited by 84
Targeting Cbl-b in cancer immunotherapy
Augustin, R. C., Bao, R., & Luke, J. J. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006007 · Cited by 101
She, Y., He, B., Wang, F., Zhong, Y., Wang, T., Liu, Z., Yang, M., Yu, B., Deng, J., Sun, X., et al. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2022.104364 · Cited by 91
Lei, M., Siemers, N. O., Pandya, D., Chang, H., Sánchez, T., Harbison, C. T., Szabó, P. M., Janjigian, Y. Y., Ott, P. A., Sharma, P., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2790 · Cited by 97
(IMI), O. B. O. T. I. M. I., Pistillo, M. P., Fontana, V., Morabito, A., Dozin, B., Laurent, S., Carosio, R., Banelli, B., Ferrero, F., Spano, L., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2258-1 · Cited by 92
Arwert, E. N., Milford, E. L., Rullan, A., Derzsi, S., Hooper, S., Kato, T., Mansfield, D., Melcher, A., Harrington, K. J., & Sahai, E. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0527-7 · Cited by 90
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors
Conroy, J. M., Pabla, S., Nesline, M., Glenn, S. T., Papanicolau‐Sengos, A., Burgher, B., Andreas, J., Giamo, V., Wang, Y., Lenzo, F. L., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0489-5 · Cited by 97
“For example, a T-cell inflamed signature based on IFN-γ genes was associated with response to anti-PD-1 therapy in multiple tumor types [35], and an algorithmic approach which combines gene expression profiling with tumor mutational burden (TMB) and PD-L1 IHC improves prediction of response to ICIs in melanoma [37].”
BackgroundToward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop
Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups, Bedognetti, D., Ceccarelli, M., Galluzzi, L., Lu, R., Palucka, K., Samayoa, J., Spranger, S., Warren, S., Wong, K.-K., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0602-4 · Cited by 88
Presti, D., Dall’Olio, F. G., Besse, B., Ribeiro, J. M., Meglio, A. D., & Soldato, D. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103773 · Cited by 99
Molecular patterns of resistance to immune checkpoint blockade in melanoma
Lauss, M., Phung, B., Borch, T. H., Harbst, K., Kaminska, K. K., Ebbesson, A., Hedenfalk, I. A., Yuan, J., Nielsen, K., Ingvar, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47425-y · Cited by 96
Røssevold, A. H., Andresen, N. K., Bjerre, C. A., Gilje, B., Jakobsen, E. H., Raj, S. X., Falk, R. S., Russnes, H. G., Jahr, T., Mathiesen, R. R., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02126-1 · Cited by 89
Advancing CAR T-Cell Therapy for Solid Tumors: Lessons Learned from Lymphoma Treatment
Titov, A., Valiullina, A., Zmievskaya, E., Zaikova, E. K., Petukhov, A., Рифкатовна, М. Р., Bulatov, E., & Rizvanov, A. A. (2020) · Cancers · doi:10.3390/cancers12010125 · Cited by 99
“Additionally, the list of potential predictors includes evaluation of tumor mutational burden (TMB) [16], combined assessment of PD-L1 expression and presence of tumor-infiltrating lymphocytes (TIL) [17], transcriptome analysis for detection of “inflammatory” genetic signatures [18], and the assessment of neoantigen l…”
BackgroundThe Resistance Mechanisms of Lung Cancer Immunotherapy
Wang, F., Wang, S., & Zhou, Q. H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.568059 · Cited by 98
Deep generative neural network for accurate drug response imputation
Jia, P., Hu, R., Pei, G., Dai, Y., Wang, Y., & Zhao, Z. (2021) · Nature Communications · doi:10.1038/s41467-021-21997-5 · Cited by 108
Immunotherapy in non-small cell lung cancer: Past, present, and future directions
Punekar, S. R., Shum, E., Grello, C., Lau, S. C. M., & Velcheti, V. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.877594 · Cited by 94
Campbell, K. M., Amouzgar, M., Pfeiffer, S. M., Howes, T. R., Medina, E., Travers, M., Steiner, G., Weber, J. S., Wolchok, J. D., Larkin, J., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.03.010 · Cited by 92
Self-citationLi, S., Li, K., Wang, K., Yu, H., Wang, X., Shi, M., Liang, Z., Zhou, Y., Hu, Y., Li, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43462-1 · Cited by 98
Liu, C., Xie, J., Lin, B., Tian, W., Wu, Y., Shan, X., Hong, L., Li, X., Liu, L., Jin, Y., et al. (2024) · Advanced Science · doi:10.1002/advs.202401061 · Cited by 103
Self-citationHallmarks of sex bias in immuno-oncology: mechanisms and therapeutic implications
Xiao, T., Lee, J., Gauntner, T. D., Velegraki, M., Lathia, J. D., & Li, Z. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00680-z · Cited by 99
Lee, E. K., Xiong, N., Cheng, S., Barry, W. T., Penson, R. T., Konstantinopoulos, P. A., Hoffman, M. A., Horowitz, N. S., Dizon, D. S., Stover, E. H., et al. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.07.028 · Cited by 95
Metadata
- Authors
- Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., Piha-Paul, S. A., Yearley, J., Seiwert, T. Y., Ribas, A., & McClanahan, T. K.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- University of Washington (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Chicago (US)
- University of California, Los Angeles (US)
- Corresponding author
- McClanahan, Terrill K.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2017-06-26
- Volume
- 127
- Issue
- 8
- Pages
- 2930-2940
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC5531419
- OpenAlex
- W2655262992
- Cited by
- 3,788
- References
- 31
- Citations by year
- 2026: 358 · 2025: 391 · 2024: 518 · 2023: 551 · 2022: 608 · 2021: 512 · 2020: 400 · 2019: 263 · 2018: 159 · 2017: 24
- FWCI
- 101.33
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- interferon-gamma, anti-PD-1 therapy, pembrolizumab, predictive biomarkers, gene expression profiles, PD-L1 expression, immune checkpoint inhibitors, melanoma, head and neck squamous cell carcinoma, adaptive immune resistance, antigen presentation, chemokine expression
- MeSH terms
- Antineoplastic Agents, Biopsy, Carcinoma, Carcinoma, Non-Small-Cell Lung, Humans, Immune System, Immunohistochemistry, Interferon-gamma, Lung Neoplasms, Melanoma, Pilot Projects, ROC Curve, Skin Neoplasms, Stomach Neoplasms, Signal Transduction, Gene Expression Regulation, Neoplastic, Treatment Outcome, Sequence Analysis, RNA, Gene Expression Profiling, Tumor Microenvironment, B7-H1 Antigen, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.